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G6PDH Glucose-6-phosphate dehydrogenase 
GHB γ-hydroxybutyrate 
Gpx-1 Glutathione peroxidase-1 
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GST Glutathione-S-transferase Yc2 subunit 
GST-Yc2 Glutathione-S-transferase Yc2 subunit 
HNE 4-hydroxynonenal 
i.p. Intraperitoneal 
IDH-1 NADP-dependent isocitrate dehydrogenase 
iNOS Hepatic-inducible nitric oxide synthase 
JNK c-Jun N-terminal kinase 
Keap1 Kelch-like ECH-associated protein 1 
LB Luria-Bertani (Medium) 
MDA Malondialdehyde 
ME1 Malic enzyme-1 
MPT Mitochondrial permeability transition 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NAPQI N-acetyl-p-benzoquinoneimine 
Nqo1 NAD(P)H dehydrogenase, quinone 1 
Nrf2 Nuclear factor erythroid 2 p45-related factor 2 
NS Not significant 
NSAIDs Non-steroidal anti-inflammatory drugs 
ORE Osmotic response element 
p38 p38 mitogen-activated protein kinase 
PEG Polyethylene Glycerol 
PI3K Phosphoinositide-3 kinase 
PK proteinase K 
PMSF Phenylmethylsulfonyl fluoride 
pNA p-nitroaniline 
















RPMI-1640 Roswell Park Memorial Institute 
SOD2 Mn-superoxide dismutase 
SSA Succinic semialdehyde 
SSADH Succinic semialdehyde dehydrogenase  
TBA Thiobarbituric acid 
TBARS Thiobarbituric acid reactive substances 
TBST Tris-buffer saline containing 0.05% Tween 20 
TCA Trichloroacetic acid 
TG Transgenic 
TMRM Tetramethylrhodamine methyl ester 
WT Wild-type 
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